Xvivo Perfusion Q3’20: Underlying Business still Strong

Research Note

2020-10-26

06:30

Sales in Q3 came in slightly higher than expected but is still highly affected by the Covid-19 situation. There are signs of improvement in the market. We see this period where sales are challenging to predict and dependent on external factors as something that will fade away going into 2021; however, the pace is somewhat uncertain. We still believe that the long-term trend is intact, and the underlying business story is still very strong. We adjust our estimates downward mainly due to the EO items, and we lower our Q4 forecast slightly. The forecasts for 2021 and onwards are marginally changed.

MH

Mats Hyttinge

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.